Hepion COO buys 4M shares and warrants

Q: What insider transactions did HEPA COO Sireesh Appajosyula report?

Appajosyula reported buying 2,000,000 Hepion common shares at $0.05 each and acquiring 2,000,000 warrants with a $0.06 exercise price on 2026-08-03, all held as direct ownership.

Q: How many HEPA shares does the COO hold after these Form 4 transactions?

After the reported transactions, the COO holds 3,250,000 Hepion common shares directly. He also owns 2,000,000 warrants exercisable into common stock, providing potential additional equity exposure if exercised before expiration.

Q: At what prices did the HEPA COO acquire shares and warrants?

The COO purchased 2,000,000 common shares at a price of $0.05 per share and acquired 2,000,000 warrants with an exercise price of $0.06 per share, giving him the right to buy common stock at that strike.

Q: When do the newly acquired HEPA warrants held by the COO expire?

The 2,000,000 warrants acquired by the COO on 2026-08-03 carry an expiration date of 2031-08-03. They are exercisable into 2,000,000 shares of Hepion common stock at a $0.06 exercise price.

Q: Were the HEPA COO’s Form 4 trades under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked, indicating these purchases were not reported as made under a Rule 10b5-1 trading plan. The trades are therefore not identified as pre-arranged plan transactions.

Hepion Pharmaceuticals, Inc. director and Chief Operating Officer Sireesh Appajosyula reported insider purchases on 2026-08-03.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director and Chief Operating Officer Sireesh Appajosyula reported insider purchases on 2026-08-03. He acquired 2,000,000 common shares at $0.05 per share and 2,000,000 warrants with a $0.06 exercise price, expiring 2031-08-03. Following these trades, he directly owns 3,250,000 common shares and 2,000,000 warrants. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 4,000,000 shares

Net Buy 2 txns

Insider Appajosyula Sireesh

Role Chief Operating Officer

Bought 4,000,000 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Warrants	2,000,000	$0.00	$0.00
Purchase	Common Stock	2,000,000	$0.05	$100K

Holdings After Transaction: Warrants — 2,000,000 contracts (Direct); Common Stock — 3,250,000 shares (Direct)

Key Figures

Common shares purchased: 2,000,000 shares Purchase price per share: $0.05 per share Warrants acquired: 2,000,000 warrants +3 more

6 metrics

Common shares purchased 2,000,000 shares Common stock bought on 2026-08-03 at $0.05 per share

Purchase price per share $0.05 per share Price paid for 2,000,000 common shares on 2026-08-03

Warrants acquired 2,000,000 warrants Warrants to buy common stock acquired on 2026-08-03

Warrant exercise price $0.06 per share Exercise price for 2,000,000 warrants expiring 2031-08-03

Warrant expiration date 2031-08-03 Expiration date of 2,000,000 warrants acquired by the COO

Common shares owned after 3,250,000 shares Direct common stock holdings following purchases on 2026-08-03

Key Terms

exercise price, expiration date, underlying security, Rule 10b5-1 trading plan

4 terms

exercise price financial

"conversion_or_exercise_price: "0.0600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2031-08-03""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

Rule 10b5-1 trading plan regulatory

"aff_10b5_one: false indicates no Rule 10b5-1 plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did HEPA COO Sireesh Appajosyula report?

Appajosyula reported buying 2,000,000 Hepion common shares at $0.05 each and acquiring 2,000,000 warrants with a $0.06 exercise price on 2026-08-03, all held as direct ownership.

How many HEPA shares does the COO hold after these Form 4 transactions?

After the reported transactions, the COO holds 3,250,000 Hepion common shares directly. He also owns 2,000,000 warrants exercisable into common stock, providing potential additional equity exposure if exercised before expiration.

At what prices did the HEPA COO acquire shares and warrants?

The COO purchased 2,000,000 common shares at a price of $0.05 per share and acquired 2,000,000 warrants with an exercise price of $0.06 per share, giving him the right to buy common stock at that strike.

When do the newly acquired HEPA warrants held by the COO expire?

The 2,000,000 warrants acquired by the COO on 2026-08-03 carry an expiration date of 2031-08-03. They are exercisable into 2,000,000 shares of Hepion common stock at a $0.06 exercise price.

Were the HEPA COO’s Form 4 trades under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked, indicating these purchases were not reported as made under a Rule 10b5-1 trading plan. The trades are therefore not identified as pre-arranged plan transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/12/2026 - 09:36 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Appajosyula Sireesh

(Last)

(First)

(Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK,

NEW JERSEY

07701

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/03/2026		P		2,000,000	A	$0.05	3,250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants	$0.06	08/03/2026		P		2,000,000		08/03/2026	08/03/2031	Common Stock	2,000,000	$0	2,000,000	D

Explanation of Responses:

	/s/ Sireesh Appajosyula	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR